The preclinical pharmacology of “Arimidex” (Anastrozole; ZD1033) — a potent, selective aromatase inhibitor
- 1 July 1996
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 58 (4) , 439-445
- https://doi.org/10.1016/0960-0760(96)00064-7
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Original article: CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer — A Phase I studyAnnals of Oncology, 1990
- A phase I trial of CGS 16949a. A new aromatase inhibitorCancer, 1990
- The New Aromatase Inhibitor CGS-16949A SuppressesAldosterone and Cortisol Production by Human Adrenal Cellsin vitroJournal of Clinical Endocrinology & Metabolism, 1989
- Inhibition of Aromatase With CGS 16949A in Postmenopausal Women*Journal of Clinical Endocrinology & Metabolism, 1989
- HYPERTENSION DURING HIGH-DOSE KETOCONAZOLE TREATMENT: A PROBABLE MINERALOCORTICOSTEROID EFFECTThe Lancet, 1987
- Inhibition of Aromatization Stimulates Luteinizing Hormone and Testosterone Secretion in Adult Male Rhesus Monkeys*Journal of Clinical Endocrinology & Metabolism, 1984
- Androgen and Estrogen Metabolism in Male Rhesus Monkeys*Endocrinology, 1979
- The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11Endocrinology, 1977
- Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applicationsThe Journal of Steroid Biochemistry and Molecular Biology, 1974
- Effects of Prolonged Inhibition of 11β-Hydroxylase in the DogEndocrinology, 1966